- Emergent BioSolutions has key niche differentiators that strengthen the operating model, with exposure to defence & public health threats.
- They hold the only FDA approved anthrax vaccine in their portfolio, and ~60% of total revenues are backed by US Government contract agreements.
- The stock has bounced formed solid support this year, in an ascending channel that has corrected since August, with volatility to the downside.
- We see a 33% value gap skewed to the upside with fair multiples and value relative to peers.
- We hold a bullish outlook for the company, and set a $122 price target over the coming 12 months, with Q3 financials an upcoming catalyst.
For further details see:
Emergent BioSolutions: Deep Value Play With 33% Upside & Military Exposure